Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma
Introduction: The appraisal of medicines is often a complex and iterative process. We compared the health technology assessment (HTA) process in England and France taking as a case study the example of ixazomib for multiple myeloma. Methods: We undertook an analysis of eight relevant published docum...
Saved in:
Main Authors: | Xavier Armoiry (Author), Hans-Martin Spath (Author), Aileen Clarke (Author), Martin Connock (Author), Paul Sutcliffe (Author), Claude Dussart (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
by: M. Haq, et al.
Published: (2021) -
Spotlight on ixazomib: potential in the treatment of multiple myeloma
by: Muz B, et al.
Published: (2016) -
Accidental Ixazomib Overdose in a Patient With Multiple Myeloma
by: Parth J. Sampat MBBS, et al.
Published: (2021) -
US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
by: Bassali J, et al.
Published: (2020) -
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
by: José-Ángel Her, et al.
Published: (2022)